English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Molluscum Contagiosum Virus Protein MC008 Targets NF-kappa B Activation by Inhibiting Ubiquitination of NEMO

MPS-Authors
/persons/resource/persons78510

Pichlmair,  Andreas
Pichlmair, Andreas / Innate Immunity, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Phelan, T., Lawler, C., Pichlmair, A., Little, M. A. A., Bowie, A. G. G., & Brady, G. (2023). Molluscum Contagiosum Virus Protein MC008 Targets NF-kappa B Activation by Inhibiting Ubiquitination of NEMO. Journal of Virology, 97(3): e00108-23. doi:10.1128/jvi.00108-23.


Cite as: https://hdl.handle.net/21.11116/0000-000C-F811-9
Abstract
Molluscum contagiosum virus (MCV) is a human-adapted poxvirus that causes a common and persistent yet mild infection characterized by distinct, contagious, papular skin lesions. These lesions are notable for having little or no inflammation associated with them and can persist for long periods without an effective clearance response from the host. Like all poxviruses, MCV encodes potent immunosuppressive proteins that perturb innate immune pathways involved in virus sensing, the interferon response, and inflammation, which collectively orchestrate antiviral immunity and clearance, with several of these pathways converging at common signaling nodes. One such node is the regulator of canonical nuclear factor kappa B (NF-kappa B) activation, NF-kappa B essential modulator (NEMO). Here, we report that the MCV protein MC008 specifically inhibits NF-kappa B through its interaction with NEMO, disrupting its early ubiquitin-mediated activation and subsequent downstream signaling. MC008 is the third NEMO-targeting inhibitor to be described in MCV to date, with each inhibiting NEMO activation in distinct ways, highlighting strong selective pressure to evolve multiple ways of disabling this key signaling protein.